专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20140187987A1 CUFF FOR ARTERIAL BLOOD PRESSURE MONITOR 审中-公开
标题翻译：血压监护仪CUFF
公开(公告)号：US20140187987A1
公开(公告)日：2014-07-03
申请号：US13730180
申请日：2012-12-28
申请人： Jacob Fraden , Justin Davidson , William Ewing
发明人： Jacob Fraden , Justin Davidson , William Ewing
IPC分类号： A61B5/022
CPC分类号： A61B5/02233
摘要： A sphygmomanometer with a cuff for use on a patient wrist, upper or lower arm incorporates an inflatable bladder and a support structure. The cuff is subdivided into two sections. The first section holds the bladder against an arterial side of the limb, while the second section abuts a non-arterial side of the limb and is mechanically coupled to the support structure. When the cuff is attached to the patient limb, the bladder is positioned to avoid receiving a gravitational force caused by the weight of the limb. Rather, the gravitational force is absorbed by the support structure in an interior area of the cuff removed from the bladder.
摘要翻译：具有用于患者腕部，上臂或下臂的袖带的血压计包括可膨胀的膀胱和支撑结构。袖口细分为两部分。第一部分将膀胱抵靠肢体的动脉侧，而第二部分邻接肢体的非动脉侧并且机械地联接到支撑结构。当袖带连接到患者肢体时，膀胱被定位成避免接收由肢体重量引起的重力。相反，引力在由从膀胱移除的袖带的内部区域中被支撑结构所吸收。

2. 发明申请

US20140041681A1 Compact, Recyclable, Multi-Layered Dental Flossing Device and Packaging Therefore 审中-公开
公开(公告)号：US20140041681A1
公开(公告)日：2014-02-13
申请号：US14112927
申请日：2012-04-20
申请人： William Ewing
发明人： William Ewing
IPC分类号： A61C15/04
CPC分类号： A61C15/041 , A61C15/00 , A61C15/043 , A61Q11/00
摘要： A compact, recyclable dental flossing device in the form of a multi-layered elongated filament or strip of a resin which has physical characteristics such that, when elongated or drawn to stop, possesses a substantially increased length and tensile strength and a reduced thickness suitable for flossing teeth.

3. 发明申请

US20060154955A1 Bicyclic heterocycles as cannabinoid receptor modulators 有权
标题翻译：双环杂环作为大麻素受体调节剂
公开(公告)号：US20060154955A1
公开(公告)日：2006-07-13
申请号：US11330540
申请日：2006-01-12
申请人： Chongqing Sun , William Ewing , Yanting Huang
发明人： Chongqing Sun , William Ewing , Yanting Huang
IPC分类号： C07D471/02 , A61K31/4745
CPC分类号： C07D471/04
摘要： The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I: including all pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R3a, R4, n, Y and Z are described herein.
摘要翻译：本申请描述了根据式I的化合物，包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物和使用根据式I的化合物的治疗方法，其单独和与一种或多种另外的治疗剂。化合物具有通式I：包括所有药学上可接受的盐和立体异构体，R 1，R 2，R 3，R 3， 3a，R 4，n，Y和Z在本文中描述。

4. 发明申请

US20060079556A1 N-sulfonylpiperidine cannabinoid receptor 1 antagonists 有权
标题翻译： N-磺酰基哌啶大麻素受体1拮抗剂
公开(公告)号：US20060079556A1
公开(公告)日：2006-04-13
申请号：US11247492
申请日：2005-10-11
申请人： Philip Sher , Gang Wu , William Ewing
发明人： Philip Sher , Gang Wu , William Ewing
IPC分类号： A61K31/454 , C07D401/02
CPC分类号： C07D401/12 , C07D211/96 , C07D409/12
摘要： The present application describes compounds according to Formula I, wherein R1, R2, R3, R4, X and Y are described herein. Additionally, the present application describes pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents. Finally, the present application describes methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents.
摘要翻译：本申请描述了根据式I的化合物，其中R 1，R 2，R 3，R 4，本文描述了X和Y。另外，本申请描述了包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物。最后，本申请描述了单独使用式I化合物和与一种或多种另外的治疗剂组合的治疗方法。

5. 发明申请

US20060067020A1 Integrated electric motor and control system and method 失效
标题翻译：集成电动机及控制系统及方法
公开(公告)号：US20060067020A1
公开(公告)日：2006-03-30
申请号：US10955734
申请日：2004-09-30
申请人： William Ewing , Michael Swinney
发明人： William Ewing , Michael Swinney
IPC分类号： H02H5/04
CPC分类号： H02K5/225 , H02K11/25
摘要： An electrically and thermally protected electrical machine is disclosed. The electrical and thermal protection is provided by one or more control components placed in a conduit box of the electrical machine to disrupt power transmission to the electrical machine upon an excessive current or temperature occurrence. Other control components may also be added to the system to provide further current or thermal protection. These additional control components may or may not be located within the conduit box. A method for providing thermal and current protection, and an aftermarket kit for adding such protection, to an electrical machine are also disclosed.
摘要翻译：公开了一种电气和热保护的电机。电气和热保护由放置在电机的导管箱中的一个或多个控制部件提供，以在过度的电流或温度发生时中断对电机的电力传输。也可以向系统添加其它控制组件以提供进一步的电流或热保护。这些额外的控制部件可能位于导管箱内，也可能不位于导管箱内。还公开了一种用于提供热和电流保护的方法以及用于将这种保护添加到电机的售后工具包。

6. 发明申请

US20050008212A1 Spot finding algorithm using image recognition software 审中-公开
标题翻译：使用图像识别软件的现货发现算法
公开(公告)号：US20050008212A1
公开(公告)日：2005-01-13
申请号：US10822035
申请日：2004-04-08
申请人： William Ewing , Duane DeSieno , Rhett Affleck
发明人： William Ewing , Duane DeSieno , Rhett Affleck
IPC分类号： G01N31/00 , G06F20060101 , G06K9/00 , G06T7/00
CPC分类号： G06T7/75 , G06T2207/30004
摘要： A plurality of samples are tested for their ability to enhance or inhibit a biological process in a multiplexed diffusive assay. The assay is imaged after the biological process has produced spots in a medium that indicate the tested enhancing or inhibiting ability of the samples. The image containing the resulting spots are evaluated to determine which samples caused the spots to form. The location of spots are identified by user selection or through a gradient triangulation technique that determines spot locations by analyzing the slope of pixel intensities in numerous subimages. The spots may also be analyzed by parametrically modeling the spots and comparing the spot characteristics in the image to a spot function, to determine the location of hit spots in the image. The hit spot locations, corresponding to the location of tested samples in the assay that enhanced or inhibited the biological process, are output to facilitate further analysis of the test samples.
摘要翻译：测试多个样品在多重扩散测定中增强或抑制生物过程的能力。在生物学过程在培养基中产生指示样品的增强或抑制能力的斑点之后，测定成像。评估含有所得斑点的图像，以确定哪些样品导致斑点形成。斑点的位置通过用户选择或通过梯度三角测量技术来识别，其通过分析许多子图像中像素强度的斜率来确定点位置。也可以通过对斑点进行参数建模和将图像中的斑点特征与斑点函数进行比较来分析斑点，以确定图像中命中点的位置。输出对应于增强或抑制生物过程的测定中测试样品的位置的命中点位置，以便于进一步分析测试样品。

7. 发明申请

US20100048612A1 BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS 有权
标题翻译：作为CANNABINOID-1受体调节剂的双相异构体
公开(公告)号：US20100048612A1
公开(公告)日：2010-02-25
申请号：US12609436
申请日：2009-10-30
申请人： Chongqing Sun , Yanting Huang , Doree F. Sitkoff , Taekyu Lee , William Ewing
发明人： Chongqing Sun , Yanting Huang , Doree F. Sitkoff , Taekyu Lee , William Ewing
IPC分类号： A61K31/437 , C07D471/04
CPC分类号： C07D471/04 , C07D487/04
摘要： The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the following general formula: including all prodrugs, solvates, pharmaceutically acceptable salts and stereoisomers, wherein A, B, R1, R2, R3 and R8 are described herein.
摘要翻译：本申请描述了根据式I的化合物，包含至少一种根据式I的化合物和任选的一种或多种另外的治疗剂的药物组合物和使用根据式I的化合物的治疗方法，其单独和与一种或多种另外的治疗剂。该化合物具有以下通式：包括所有前药，溶剂化物，药学上可接受的盐和立体异构体，其中A，B，R 1，R 2，R 3和R 8在本文中描述。

8. 发明申请

US20070021346A1 N-terminally modified GLP-1 receptor modulators 审中-公开
标题翻译： N-末端修饰的GLP-1受体调节剂
公开(公告)号：US20070021346A1
公开(公告)日：2007-01-25
申请号：US11442017
申请日：2006-05-26
申请人： William Ewing , Claudio Mapelli , Douglas Riexinger , Ving Lee , Richard Sulsky , Yeheng Zhu
发明人： William Ewing , Claudio Mapelli , Douglas Riexinger , Ving Lee , Richard Sulsky , Yeheng Zhu
IPC分类号： A61K38/10 , C07K7/08
CPC分类号： C07K14/605 , A61K38/00
摘要： The subject matter described herein provides novel human glucagon-like peptide-1 (GLP-1) receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. The described compounds include chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The disclosed and claimed peptides show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.
摘要翻译：本文所述的主题提供具有与天然GLP-1肽相似或优于天然GLP-1肽的生物活性的新型人胰高血糖素样肽-1（GLP-1）受体调节剂，因此可用于治疗或预防与GLP相关的疾病或病症活动。所述化合物包括化学修饰的肽，其不仅刺激II型糖尿病患者的胰岛素分泌，而且产生其它有益的促胰岛素反应。这些合成肽GLP-1受体调节剂表现出增加的蛋白水解切割的稳定性，使其成为口服或肠胃外给药的理想治疗候选物。所公开和要求保护的肽在糖尿病的功效模型中显示出所需的药代动力学性质和期望的效力。

9. 发明申请

US20060287242A1 Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions 有权
标题翻译：人胰高血糖素样肽-1调节剂及其在治疗糖尿病和相关病症中的应用
公开(公告)号：US20060287242A1
公开(公告)日：2006-12-21
申请号：US11170968
申请日：2005-06-30
申请人： William Ewing , Claudio Mapelli , Richard Sulsky , Tasir Haque , Ving Lee , Douglas Riexinger , Rogelio Martinez , Yeheng Zhu
发明人： William Ewing , Claudio Mapelli , Richard Sulsky , Tasir Haque , Ving Lee , Douglas Riexinger , Rogelio Martinez , Yeheng Zhu
IPC分类号： A61K38/10 , C07K7/08
CPC分类号： C07K7/06 , A61K38/00 , C07K14/605
摘要： The present invention provides novel human glucagon-like peptide-1 (GLP-1)-receptor modulators that have biological activity similar or superior to native GLP-1 peptide and thus are useful for the treatment or prevention of diseases or disorders associated with GLP activity. Further, the present invention provides novel, chemically modified peptides that not only stimulate insulin secretion in type II diabetics, but also produce other beneficial insulinotropic responses. These synthetic peptide GLP-1 receptor modulators exhibit increased stability to proteolytic cleavage making them ideal therapeutic candidates for oral or parenteral administration. The peptides of this invention show desirable pharmacokinetic properties and desirable potency in efficacy models of diabetes.
摘要翻译：本发明提供了具有与天然GLP-1肽相似或优于天然GLP-1肽的生物活性的新型人胰高血糖素样肽-1（GLP-1） - 受体调节剂，因此可用于治疗或预防与GLP活性相关的疾病或病症。此外，本发明提供新颖的化学修饰的肽，其不仅刺激II型糖尿病患者的胰岛素分泌，而且产生其它有益的促胰岛素反应。这些合成肽GLP-1受体调节剂表现出增加的蛋白水解切割的稳定性，使其成为口服或肠胃外给药的理想治疗候选物。本发明的肽在糖尿病的功效模型中显示出所需的药代动力学性质和期望的效力。

10. 发明申请

US20050043322A1 Substituted dihydropyrimidine inhibitors of calcium channel function 有权
标题翻译：取代二氢嘧啶抑制剂钙通道功能
公开(公告)号：US20050043322A1
公开(公告)日：2005-02-24
申请号：US10897040
申请日：2004-07-23
申请人： Natesan Murugesan , Gergory Bisacchi , William Ewing , Zhengxiang Gu
发明人： Natesan Murugesan , Gergory Bisacchi , William Ewing , Zhengxiang Gu
IPC分类号： A61K20060101 , A61K31/506 , A61K31/513 , C07D239/22 , C07D43/02
CPC分类号： C07D403/12 , C07D239/26 , C07D239/36
摘要： The present invention relates to substituted dihydropyrimidine inhibitors of calcium channel function having formula I where A, a, J, R1, R2 R3, R4, and R5, are defined herein; pharmaceutical compositions comprising said compounds; and methods of treating calcium channel-dependent disorders, including hypertension.
摘要翻译：本发明涉及具有式I的钙通道官能团的取代二氢嘧啶抑制剂，其中A，a，J，R 1，R 2，R 3，R 4和R 5定义如下 ; 包含所述化合物的药物组合物; 以及治疗钙通道依赖性疾病（包括高血压）的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式